Benjamin Emmanuel - Epidemiology

Author Information

Benjamin Emmanuel is a prominent researcher affiliated with the EMBLEM Study at the African Field Epidemiology Network in Kampala, Uganda, as well as the Institute of Human Virology at the University of Maryland School of Medicine in Baltimore, USA. His work primarily focuses on the epidemiological and virological aspects of infectious diseases, particularly hepatitis C. With a strong background in field epidemiology and virology, Benjamin Emmanuel has contributed significantly to understanding and improving healthcare delivery for viral infections, especially in resource-limited settings.

Research Contributions

Benjamin Emmanuel has made substantial contributions to the study of hepatitis C, particularly in the context of co-infections with HIV and the metabolic changes associated with hepatitis C. His research spans the exploration of DNA methylation and immune markers, immunological recovery post-viral response, and the efficacy of direct-acting antiviral therapies. Notably, he has been involved in studies that focus on treatment expansion and implementation of hepatitis C care models in resource-limited settings like Rwanda. His work aims to enhance the management and treatment outcomes for chronic hepatitis C patients, providing insights into virologic responses and improving long-term health outcomes.

Aliases

Benjamin Emmanuel is also known by several aliases, including B Emmanuel and B. Emmanuel. These variations are used interchangeably across different publications and citations.

Publication and Citation Metrics

Metric	Value
Total Papers	40
Total Citations	851
H-index	16

Publications:

DNA Methylation and Immune Cell Markers Demonstrate Evidence of Accelerated Aging in Patients with Chronic HBV or HCV, with or without HIV Co-Infection.

DOI: 10.1093/cid/ciaa1371

Year: 2020

Immunological recovery in T-cell activation after sustained virologic response among HIV positive and HIV negative chronic Hepatitis C patients

DOI: 10.1007/s12072-019-09941-8

Year: 2019

Metabolic Changes in Chronic Hepatitis C Patients who Carry IFNL4-ΔG and Achieve Sustained Virologic Response with Direct-Acting Antiviral Therapy.

DOI: 10.1093/infdis/jiz435

Year: 2019

A Pilot Study of Safety and Efficacy of HCV Retreatment with sofosbuvir/velpatasvir/voxilaprevir in Patients With or Without HIV (RESOLVE STUDY).

DOI: 10.1016/j.jhep.2019.05.021

Year: 2019

Minimal monitoring of direct-acting antiviral therapy within a real world, urban population

DOI: 10.1016/s0168-8278(18)30831-6

Year: 2018

Recovery of hepatitis C specific T‐cell responses after rituximab therapy in hepatitis C mixed cryoglobulinemic vasculitis

DOI: 10.1002/jmv.25002

Year: 2018

Implementation of a unique hepatitis C care continuum model in a resource limited setting

DOI: 10.1016/S0168-8278(18)30868-7

Year: 2018

Implementation of a unique hepatitis C care continuum model in Rwanda.

DOI: 10.1093/pubmed/fdy115

Year: 2018

Sustained virologic response leading to improved long-term metabolic outcomes

DOI: 10.1016/S0168-8278(18)31330-8

Year: 2018

Expansion of Treatment for Hepatitis C Virus Infection

DOI: 10.7326/L17-0698

Year: 2018

What is the Future of Informatica in Epidemiology?

How to Frame the Message?

What are Model Parameters?

How Does Delayed Diagnosis Impact Patient Outcomes?

What Are the Primary Benefits of Epidemiology?

How Can Interventions be Designed to Promote Equity?

What Risk Factors Are Associated with Tumor Development?

How Can Epidemiological Studies Help Cyclists?

How Does the Hawthorne Effect Manifest?

Why are Educational Campaigns Important?

Partnered Content Networks

Relevant Topics